“

The UK is an important market for us. There are many countries in Europe, namely Switzerland, which are not in the EU, and we continue to invest in those countries as well as in the EU, we will continue to invest strongly in the UK despite the decision to exit the EU as we see very large areas of unmet medical need and the innovation Novartis brings can help patients in the UK.